Search results
Results from the WOW.Com Content Network
AAFP 2022 [4] [5] General <140/90 BP >140/90 and low-risk for CVD: Lifestyle changes BP >140/90 and CVD risk factors or failed lifestyle changes: monotherapy with thiazide-type diuretic, ACEI/ARB, and/or CCB BP >160/100: Two from different classes: thiazide-type diuretic, ACEI/ARB, and/or CCB WHO 2021 [6] General High CVD risk, diabetes or CKD
[10] Potential side effects include angioedema, nephrotoxicity, and low blood pressure. [10] It was approved for medical use in the United States and in the European Union in 2015, [11] [12] [13] [7] and in Australia in 2016. [1] In 2022, it was the 165th most commonly prescribed medication in the United States, with more than 3 million ...
Dapagliflozin is an example of an SGLT-2 inhibitor, it is a competitive, highly selective inhibitor of SGLT. It acts via selective and potent inhibition of SGLT-2, and its activity is based on each patient's underlying blood sugar control and kidney function. The results are decreased kidney reabsorption of glucose, glucosuria effect increases ...
Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and works by increasing sugar loss in urine. [2] Empagliflozin was approved for medical use in the United States and in the European Union in 2014. [13] [23] [24] It is on the World Health Organization's List of Essential Medicines. [25]
Peters has been part of multiple guideline writing groups and has written national and international guidelines. These include guidelines for transitioning care, [ 9 ] the management of type 1 [ 10 ] and type 2 diabetes [ 11 ] [ 12 ] and use of diabetes devices.
AOL
Plates vi & vii of the Edwin Smith Papyrus (around the 17th century BC), among the earliest medical guidelines. A medical guideline (also called a clinical guideline, standard treatment guideline, or clinical practice guideline) is a document with the aim of guiding decisions and criteria regarding diagnosis, management, and treatment in specific areas of healthcare.
Which conditions are risk factors for MACE depends on some characteristics of the investigated cohort. Established risk indicators in the general population include age, pre-existing cardiovascular disease, smoking, diabetes mellitus, elevated concentrations of triglycerides and non-HDL cholesterol concentration, reduced HDL concentration and hypertension, as, e. g., demonstrated by the ...